<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Small cell carcinoma of the bladder</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Small cell carcinoma of the bladder</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Small cell carcinoma of the bladder</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Tanya B Dorff, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joaquim Bellmunt, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 19, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Small cell carcinoma (SCC) of the bladder is an aggressive, poorly differentiated neuroendocrine neoplasm that is similar to SCC of the lung in clinical behavior.</p><p>Although SCC is classified as a discrete entity, molecular studies have indicated that SCC is derived from the same clonal population as urothelial carcinoma (also known as transitional cell carcinoma) [<a href="#rid1">1</a>]. Bladder SCC is frequently found in conjunction with other histologic forms of bladder cancer [<a href="#rid2">2-4</a>]. As an example, in a series of 64 cases, 44 (68 percent) had other tumor types present, including elements of urothelial cancer in 38 cases (58 percent of the total series) [<a href="#rid2">2</a>]. Similarly, another series of 51 cases of SCC reported that elements of urothelial carcinoma, adenocarcinoma, and squamous cell carcinoma were seen in 70, 8, and 10 percent of the cases, respectively [<a href="#rid3">3</a>].</p><p>SCC of the bladder will be reviewed here. Extrapulmonary SCC at other sites is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4882.html" rel="external">"Extrapulmonary small cell cancer"</a>.)</p><p class="headingAnchor" id="H760197410"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>SCC of the bladder is a rare neoplasm. For example, in the United States, it accounts for roughly 500 new cases annually. The incidence of SCC of the bladder may be increasing, based upon Surveillance, Epidemiology, and End Results (SEER)-Medicare data from the United States where the incidence rose from 0.05 to 0.14 cases per 100,000 population between 1991 and 2005 [<a href="#rid5">5</a>], but this still represents fewer than 1 percent of all bladder tumors [<a href="#rid6">6</a>].</p><p>Analyses of patients with SCC of the bladder from two databases (SEER and the National Cancer Database) noted the following [<a href="#rid5">5,7</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Men are affected more commonly than women (76 versus 24 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The median age at diagnosis is 73 years, with older adults (age &gt;75 years) having a poorer prognosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Median overall survival varies substantially based on the stage of disease. Median overall survival is approximately 11 months across the entire population [<a href="#rid5">5</a>] and 21 months for those with localized SCC [<a href="#rid7">7</a>].</p><p></p><p>A past history of smoking has been associated with SCC of the bladder [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H694747845"><span class="h1">MOLECULAR BASIS OF DISEASE</span><span class="headingEndMark"> — </span>Some molecular studies indicate that SCC is derived from the same clonal population as urothelial carcinoma. Despite this, emerging data suggest that the genetics of SCC of the bladder are different from that of conventional urothelial-derived cancer, with a distinct molecular phenotype and involved pathways. </p><p>Notable genetic and molecular findings in SCC of the bladder include:</p><p class="bulletIndent1"><span class="glyph">●</span>Frequent loss of heterozygosity at 3p25-26, which encompasses the von Hippel-Lindau (<em>VHL</em>) tumor suppressor gene [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Telomerase reverse transcriptase (<em>TERT</em>) promoter mutations are common, occurring in 100 percent of cases in one observational study [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>More common or higher expression of progestin receptor, c-kit, topoisomerase 2, tubulin 3, ribonucleotide reductase subunit M1, and topoisomerase 1 [<a href="#rid10">10</a>]. Conversely, expression of nectin 4 in SCC of the bladder is rarely detected [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Epigenetic alterations are noted to be important, with methylation silencing of the promoter for tumor suppressor genes including mut L homolog 1 (<em>MLH1</em>) and O-6-methylguanine DNA methyltransferase (<em>MGMT</em>) [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Deletions at 10q, 4q, 5q, and 13q, with candidate genes including phosphatase and tensin homolog (<em>PTEN</em>) loss (10q23) and retinoblastoma (<em>RB</em>) loss (13q14) [<a href="#rid12">12</a>]. Fibroblast growth factor receptor mutations and translocations do not appear to be common in SCC.</p><p></p><p>Overexpression of actionable mutations such as c-kit [<a href="#rid10">10</a>], epidermal growth factor receptor (EGFR) [<a href="#rid13">13</a>], and somatostatin receptors [<a href="#rid14">14</a>] has also been noted in a substantial proportion of SCC of the bladder tissues. It is unknown whether targeting these alterations will improve clinical outcomes.</p><p class="headingAnchor" id="H2"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>The clinical features of SCC of the bladder are similar to those of other bladder tumors and reflect the presence of a mass.</p><p>In a Rare Cancer Network series of 107 patients, the following presenting symptoms were observed [<a href="#rid15">15</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Hematuria (86 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Ureteral obstruction and acute renal failure (13 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Dysuria and frequency (29 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Hematospermia (n = 1)</p><p class="bulletIndent1"><span class="glyph">●</span>Recurrent urinary tract infections (n = 1)</p><p></p><p>In another series, the diagnosis of SCC was incidentally made in 7 percent of patients during surveillance cystoscopy following a prior diagnosis of urothelial carcinoma. SCC is sometimes identified during surgery for a bladder tumor whose histology initially appeared to be urothelial based upon transurethral resection of bladder tumor (TURBT). Paraneoplastic syndromes can occur but are less common than with SCC of the lung [<a href="#rid16">16</a>]. (See  <a class="medical medical_review" href="/z/d/html/4641.html" rel="external">"Clinical manifestations of lung cancer", section on 'Paraneoplastic phenomena'</a>.)</p><p class="headingAnchor" id="H27382496"><span class="h1">DIAGNOSTIC WORKUP</span><span class="headingEndMark"> — </span>The workup of SCC of the bladder mirrors that for other bladder cancers. (See  <a class="medical medical_review" href="/z/d/html/2989.html" rel="external">"Clinical presentation, diagnosis, and staging of bladder cancer", section on 'Initial evaluation'</a>.)</p><p>On cystoscopy, the most common sites involved tend to be the lateral wall or the bladder dome, although any area of the bladder can be involved.</p><p class="headingAnchor" id="H3"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of SCC of the bladder is generally made by histopathological examination of a tissue specimen from a transurethral biopsy or resection of a tumor. The pathology of SCC of the bladder is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2967.html" rel="external">"Pathology of bladder neoplasms", section on 'Small cell carcinoma'</a>.)</p><p class="headingAnchor" id="H27382522"><span class="h1">STAGING</span><span class="headingEndMark"> — </span>The staging of SCC of the bladder uses the same tumor, node, metastasis (TNM) system as is used for other bladder cancer  (<a class="graphic graphic_table graphicRef110763" href="/z/d/graphic/110763.html" rel="external">table 1</a>). However, unlike management of urothelial carcinoma, management of SCC of the bladder is the same for stages I, II, and III, so staging is of less importance in this disease. (See  <a class="medical medical_review" href="/z/d/html/2989.html" rel="external">"Clinical presentation, diagnosis, and staging of bladder cancer", section on 'Staging'</a>.)</p><p>The majority of patients tend to present with advanced disease. In the 2011 Surveillance, Epidemiology, and End Results (SEER) database study, the stage of disease at presentation was [<a href="#rid5">5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Stage I – 12 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Stage II – 32 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Stage III – 14 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Stage IV – 36 percent </p><p></p><p>Due to the high rate of metastases, the initial evaluation should include computed tomography (CT) and/or magnetic resonance imaging (MRI) of the chest, abdomen, and pelvis. Brain imaging should be considered for patients with advanced-stage disease (T3b, node positive, metastatic).</p><p class="headingAnchor" id="H4"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>There are no randomized clinical trials upon which to base recommendations for the management of SCC of the bladder. However, several retrospective series and one prospective phase II study provide some insights.</p><p class="headingAnchor" id="H1784922272"><span class="h2">Selection of therapy</span><span class="headingEndMark"> — </span>Unlike urothelial carcinoma of the bladder, the presence or absence of muscle invasion does not affect treatment decisions for SCC because SCC has a much greater propensity to metastasize regardless of T stage. Therefore, the treatment is the same for T1, T2, and T3 tumors.</p><p>Our approach depends on whether disease is localized to the bladder or not:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with SCC of the bladder with localized disease and no evidence of disseminated metastases (stage I, II, or III disease), we suggest neoadjuvant chemotherapy followed by local therapy. However, patients who have already undergone radical cystectomy may be offered adjuvant chemotherapy with the rationale that cure with surgery alone is rare [<a href="#rid17">17,18</a>]. (See <a class="local">'Neoadjuvant chemotherapy plus definitive local therapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who are surgical candidates, we proceed with radical cystectomy. (See <a class="local">'Cystectomy alone'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who are unable to undergo surgery for whatever reason, we offer definitive radiation therapy (RT). (See <a class="local">'Neoadjuvant chemotherapy plus radiation therapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with SCC of the bladder and evidence of metastatic disease, we administer systemic chemotherapy utilizing a regimen with activity in SCC. Our preference is to use <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a> plus <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> (EP). (See <a class="local">'Metastatic disease'</a> below.)</p><p></p><p class="headingAnchor" id="H5"><span class="h2">Disease localized to the bladder</span><span class="headingEndMark"> — </span>Patients with SCC of the bladder have a poor prognosis, even when disease appears to be localized, due to the development of disseminated disease in a large proportion of cases [<a href="#rid2">2,6,19,20</a>]. </p><p>Although there are no randomized trials establishing the benefit of perioperative chemotherapy, retrospective data suggest that perioperative chemotherapy improves overall survival (OS) when added to cystectomy for localized small cell bladder cancer. Our preference is to administer neoadjuvant chemotherapy prior to surgery for these patients. For patients who undergo surgery without chemotherapy, which then identifies SCC or a significant component of SCC, we recommend postoperative (adjuvant) chemotherapy, with a platinum and <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a> being our preferred regimen. (See <a class="local">'Neoadjuvant chemotherapy plus definitive local therapy'</a> below.)</p><p>While the role of definitive local therapy (cystectomy or RT) has not been prospectively studied, data from neoadjuvant studies in urothelial cancer suggest that not treating the primary cancer in addition to systemic therapy risks leaving residual cancer incompletely treated.</p><p class="headingAnchor" id="H27379989"><span class="h3">Neoadjuvant chemotherapy plus definitive local therapy</span><span class="headingEndMark"> — </span>The most widely reported approach has been to use neoadjuvant chemotherapy using regimens with activity in SCC of the lung [<a href="#rid19">19,21-25</a>]. For patients in whom a response to chemotherapy is achieved, this is followed by locoregional primary tumor-directed treatment using either cystectomy or RT. Patients who progress on or do not respond to neoadjuvant chemotherapy are treated similarly to those who present with metastatic disease. (See <a class="local">'Metastatic disease'</a> below.)</p><p>There are no definitive data to indicate whether radical cystectomy or definitive RT improves the outcome compared with chemotherapy alone, nor whether there is any difference in outcome with cystectomy versus RT. However, retrospective data consistently find multimodal therapy is associated with improved survival. As with muscle-invasive urothelial bladder cancer, we prefer cystectomy with pelvic lymph node dissection to RT following completion of neoadjuvant chemotherapy because of better potential for local cancer control and the probability of occult cancer in the bladder even after response to chemotherapy.</p><p>In one retrospective review of 625 patients with localized or locally advanced bladder cancer from the National Cancer Database, the three-year survival rate was higher in patients who underwent neoadjuvant chemotherapy plus cystectomy compared with radical cystectomy (53 versus 35 percent) or treatment for bladder preservation (23 percent) [<a href="#rid17">17</a>]. Although the data are of low quality, they support the use of cystectomy after neoadjuvant chemotherapy [<a href="#rid26">26</a>]. (See  <a class="medical medical_review" href="/z/d/html/2978.html" rel="external">"Overview of the initial approach and management of urothelial bladder cancer", section on 'Muscle invasive disease'</a>.)</p><p class="headingAnchor" id="H27379995"><span class="h4">Neoadjuvant chemotherapy plus cystectomy</span><span class="headingEndMark"> — </span>The use of neoadjuvant chemotherapy appears to improve survival compared with initial cystectomy.</p><p>In a retrospective series from MD Anderson over a 25-year period, 95 patients who were surgical candidates were treated either with neoadjuvant chemotherapy (48 cases) or initial cystectomy (47 cases, 21 of whom received subsequent adjuvant chemotherapy) [<a href="#rid24">24</a>]. A variety of chemotherapy regimens were used as neoadjuvant therapy, with the majority receiving either EP, or <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">ifosfamide</a> plus <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a>. The five-year disease-specific survival was significantly longer in patients treated with neoadjuvant chemotherapy (79 versus 20 percent with initial cystectomy). In patients treated with initial cystectomy, adjuvant chemotherapy did not appear to increase OS (median 18 months either with or without adjuvant chemotherapy).</p><p>A subsequent prospective phase II study included 18 patients with clinically localized SCC of the bladder who underwent neoadjuvant chemotherapy. Chemotherapy consisted of four cycles of <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">ifosfamide</a> plus <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a> alternating with the combination of EP [<a href="#rid21">21</a>]. At cystectomy, 14 of 18 patients (78 percent) either had no evidence of residual disease or only carcinoma in situ. The median OS was 58 months. Thirteen of the 18 patients were alive and disease free.</p><p>Small retrospective analyses have suggested that adjuvant therapy may have some activity:</p><p class="bulletIndent1"><span class="glyph">●</span>Retrospective data from the Mayo Clinic reported on 68 patients with small cell bladder cancer treated with cystectomy between 1980 and 2005 [<a href="#rid4">4,27</a>]. The 18 patients receiving postoperative chemotherapy had significantly improved five-year OS compared with patients who did not receive adjuvant chemotherapy (43 versus 20 percent) [<a href="#rid27">27</a>]. Only two patients received neoadjuvant chemotherapy in this cohort.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the University of Southern California experience, 25 patients with neuroendocrine bladder cancer getting cystectomy between 1971 and 2004 showed an improved relapse-free survival and OS for those receiving perioperative chemotherapy, which was mostly given in the postoperative setting [<a href="#rid19">19</a>]. Further follow-up and expansion on this cohort showed that perioperative chemotherapy and radiological response to neoadjuvant therapy were associated with better OS, while there was a trend toward better outcome with administration of neoadjuvant therapy (unpublished data).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A series of 38 patients from the Fox Chase Cancer Center reported that a majority of long-term survivors received neoadjuvant platin-based chemotherapy followed by cystectomy, with pathologic downstaging of disease occurring in 9 of 21 patients (45 percent) [<a href="#rid25">25</a>].</p><p></p><p class="headingAnchor" id="H27380041"><span class="h4">Neoadjuvant chemotherapy plus radiation therapy</span><span class="headingEndMark"> — </span>RT has been used as an alternative to cystectomy at many centers [<a href="#rid22">22,23,28-30</a>]. In the largest study, 17 patients with SCC of the bladder underwent transurethral resection of their tumor and were then treated with platinum-based chemotherapy followed by RT [<a href="#rid22">22</a>]. A complete local response was achieved in 15 (88 percent). The median OS was 33 months. Four patients eventually had a local recurrence, while seven patients remained disease-free.</p><p>Given the lack of prospective data comparing RT with cystectomy in these patients, we generally reserve RT for patients who are not candidates for or refuse cystectomy.</p><p class="headingAnchor" id="H6"><span class="h3">Cystectomy alone</span><span class="headingEndMark"> — </span>Cystectomy alone for SCC of the bladder is associated with a poor prognosis and a relatively low cure rate [<a href="#rid19">19,24,27</a>].</p><p>The role of cystectomy alone is illustrated by an analysis of 64 cases from five university hospitals in the United States and Europe; 59 percent of patients underwent cystectomy, while 41 percent did not [<a href="#rid2">2</a>]. There was no significant difference in survival between patients who underwent cystectomy alone and patients who received combined-modality treatments. The one-year disease-specific survival rate among patients who underwent cystectomy only was 45 percent, compared with 66 percent among patients who received combination therapy. It should be pointed out that this was not a prospective study and that other small retrospective series also support a role for chemotherapy in the perioperative setting. (See <a class="local">'Neoadjuvant chemotherapy plus cystectomy'</a> above.)</p><p>The poor outcome from cystectomy alone was also illustrated by a retrospective series of 25 patients who were initially managed with cystectomy at MD Anderson [<a href="#rid18">18</a>]. The five-year cancer-specific survival was 36 percent. Other series report similar or worse outcomes for cystectomy alone.</p><p class="headingAnchor" id="H1483044238"><span class="h3">Role of prophylactic cranial irradiation</span><span class="headingEndMark"> — </span>For SCC of the bladder, prophylactic cranial irradiation (PCI) is not routinely recommended because there appears to be a lower incidence of brain metastases in extrapulmonary SCC compared with small cell lung cancer [<a href="#rid31">31,32</a>]. In the absence of data showing benefit from PCI for extrapulmonary SCC, and in view of the documented side effects of whole-brain irradiation, we do not recommend PCI for SCC of the bladder.</p><p>However, there should be a low threshold for cranial imaging as part of staging and restaging, when clinically appropriate (high T stage, or symptoms or signs suggestive of central nervous system disease). (See  <a class="medical medical_review" href="/z/d/html/4882.html" rel="external">"Extrapulmonary small cell cancer"</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Metastatic disease</span><span class="headingEndMark"> — </span>Metastatic SCC of the bladder is highly responsive to chemotherapy regimens similar to those used in SCC of the lung [<a href="#rid21">21,28</a>]. Median survival is approximately 7 to 13 months [<a href="#rid21">21,33</a>]. However, these responses are generally transient, and most patients eventually relapse.</p><p>Although brain metastases are a frequent complication in patients with SCC of the lung, they do not appear to be a common manifestation of metastatic disease among patients with SCC of the bladder [<a href="#rid18">18,28,33-35</a>]. In a pooled analysis of over 340 patients, only 37 (11 percent) were diagnosed with brain metastases [<a href="#rid34">34</a>].</p><p class="headingAnchor" id="H27382868"><span class="h3">Systemic chemotherapy</span><span class="headingEndMark"> — </span>Although systemic chemotherapy is the treatment of choice for metastatic disease, there are less data to guide the choice of a preferred regimen. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metastatic treatment-naïve SCC </strong>– The most commonly administered regimen consists of <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a> plus <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> (EP). For patients who are at a high risk for cisplatin-induced toxicity, <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> is a reasonable alternative. This preference for EP is extrapolated from the treatment of SCC of the lung. (See  <a class="medical medical_review" href="/z/d/html/4633.html" rel="external">"Extensive-stage small cell lung cancer: Initial management"</a>.)</p><p></p><p class="bulletIndent1">The data on chemotherapy for patients with metastatic treatment-naïve SCC are limited. In one prospective trial, 12 patients with stage IV disease at presentation (five with only lymph node involvement and seven with involvement at other sites with or without lymph node disease) were treated with alternating regimens of <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">ifosfamide</a> plus <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a> and EP [<a href="#rid21">21</a>]. Three patients had a complete response and underwent surgical consolidation. The median OS for this cohort was 13 months, but one patient remained disease-free for 28 months after the original treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Relapsed or refractory SCC </strong>– For patients who have progressed on EP, the treatment approach should mirror that for patients with SCC of the lung. Although many centers have published their experience, they have reported either very small numbers and/or have used different regimens for different patients, making it very challenging to estimate response rates and outcomes for specific regimens [<a href="#rid4">4,33,36</a>]. (See  <a class="medical medical_review" href="/z/d/html/4614.html" rel="external">"Treatment of refractory and relapsed small cell lung cancer"</a>.)</p><p></p><p class="headingAnchor" id="H3728245130"><span class="h3">Is there a role for immunotherapy?</span><span class="headingEndMark"> — </span>The role of checkpoint inhibitor immunotherapy in small cell carcinoma of the bladder remains under investigation. Given limited data for this approach, patients are encouraged to participate in clinical trials, where available.</p><p>Systemic therapy for SCC of the bladder has been mainly extrapolated from the treatment of small cell lung cancer (SCLC), which incorporates immunotherapy into initial management. Further details on the treatment of SCLC is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4634.html" rel="external">"Limited-stage small cell lung cancer: Initial management"</a> and  <a class="medical medical_review" href="/z/d/html/4633.html" rel="external">"Extensive-stage small cell lung cancer: Initial management"</a>.)</p><p>There are emerging data regarding the use of immunotherapy in SCC of the bladder, such as <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> in patients with chemotherapy-refractory disease [<a href="#rid37">37</a>], although expression rates of programmed cell death ligand 1 (PD-L1) and tumor-infiltrating lymphocytes are low in this disease [<a href="#rid38">38</a>]. As such, the efficacy of immunotherapy in SCC of the bladder remains to be proven.</p><p class="headingAnchor" id="H3519257546"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/122007.html" rel="external">"Society guideline links: Bladder cancer"</a>.)</p><p class="headingAnchor" id="H12"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – Small cell carcinoma (SCC) of the bladder is an aggressive tumor that typically presents with locally advanced or disseminated disease. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of</strong> <strong>localized disease</strong> – Our approach to the management of patients with disease localized to the bladder is as follows (see <a class="local">'Disease localized to the bladder'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Neoadjuvant chemotherapy prior to cystectomy</strong> – For patients with localized disease and no evidence of disseminated metastases (stage I, II or III) whose overall condition permits aggressive therapy, we suggest neoadjuvant chemotherapy using a platinum-based combination (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). For patients who respond to treatment, we suggest cystectomy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Neoadjuvant chemotherapy plus cystectomy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>No neoadjuvant chemotherapy prior to cystectomy</strong> – In patients who did not receive neoadjuvant chemotherapy prior to cystectomy, we suggest adjuvant platinum-based combination chemotherapy if the overall condition of the patient permits (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Our preferred regimen for chemotherapy is <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> and <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a>. (See <a class="local">'Disease localized to the bladder'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>No PCI</strong> – Following definitive treatment, we suggest not administering prophylactic cranial irradiation (PCI) for these patients (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Role of prophylactic cranial irradiation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of</strong> <strong>metastatic disease</strong> – For patients who do not respond to neoadjuvant therapy and for those who present with disseminated disease, we proceed with systemic chemotherapy. (See <a class="local">'Metastatic disease'</a> above and  <a class="medical medical_review" href="/z/d/html/4633.html" rel="external">"Extensive-stage small cell lung cancer: Initial management"</a>.)</p><p></p><p class="bulletIndent1">We suggest the use of regimens that are active in advanced SCC of the lung (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>), including <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> and <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a> for previously untreated patients, and agents including <a class="drug drug_general" data-topicid="10007" href="/z/d/drug information/10007.html" rel="external">topotecan</a>, anthracyclines, alkylating agents, and vinca alkaloids. </p><p></p><p class="headingAnchor" id="H11106530"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Timothy Gilligan, MD, and David I Quinn, MBBS (Hons I), PhD, FRACP, FACP, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Cheng L, Jones TD, McCarthy RP, et al. Molecular genetic evidence for a common clonal origin of urinary bladder small cell carcinoma and coexisting urothelial carcinoma. Am J Pathol 2005; 166:1533.</a></li><li><a class="nounderline abstract_t">Cheng L, Pan CX, Yang XJ, et al. Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 64 patients. Cancer 2004; 101:957.</a></li><li><a class="nounderline abstract_t">Abrahams NA, Moran C, Reyes AO, et al. Small cell carcinoma of the bladder: a contemporary clinicopathological study of 51 cases. Histopathology 2005; 46:57.</a></li><li><a class="nounderline abstract_t">Choong NW, Quevedo JF, Kaur JS. Small cell carcinoma of the urinary bladder. The Mayo Clinic experience. Cancer 2005; 103:1172.</a></li><li><a class="nounderline abstract_t">Koay EJ, Teh BS, Paulino AC, Butler EB. A Surveillance, Epidemiology, and End Results analysis of small cell carcinoma of the bladder: epidemiology, prognostic variables, and treatment trends. Cancer 2011; 117:5325.</a></li><li><a class="nounderline abstract_t">Sved P, Gomez P, Manoharan M, et al. Small cell carcinoma of the bladder. BJU Int 2004; 94:12.</a></li><li><a class="nounderline abstract_t">Fischer-Valuck BW, Rao YJ, Henke LE, et al. Treatment Patterns and Survival Outcomes for Patients with Small Cell Carcinoma of the Bladder. Eur Urol Focus 2018; 4:900.</a></li><li><a class="nounderline abstract_t">Pan CX, Zhang H, Lara PN Jr, Cheng L. Small-cell carcinoma of the urinary bladder: diagnosis and management. Expert Rev Anticancer Ther 2006; 6:1707.</a></li><li><a class="nounderline abstract_t">Zheng X, Zhuge J, Bezerra SM, et al. High frequency of TERT promoter mutation in small cell carcinoma of bladder, but not in small cell carcinoma of other origins. J Hematol Oncol 2014; 7:47.</a></li><li><a class="nounderline abstract_t">Millis SZ, Bryant D, Basu G, et al. Molecular profiling of infiltrating urothelial carcinoma of bladder and nonbladder origin. Clin Genitourin Cancer 2015; 13:e37.</a></li><li><a class="nounderline abstract_t">Hoffman-Censits JH, Lombardo KA, Parimi V, et al. Expression of Nectin-4 in Bladder Urothelial Carcinoma, in Morphologic Variants, and Nonurothelial Histotypes. Appl Immunohistochem Mol Morphol 2021; 29:619.</a></li><li><a class="nounderline abstract_t">Terracciano L, Richter J, Tornillo L, et al. Chromosomal imbalances in small cell carcinomas of the urinary bladder. J Pathol 1999; 189:230.</a></li><li><a class="nounderline abstract_t">Wang X, Zhang S, MacLennan GT, et al. Epidermal growth factor receptor protein expression and gene amplification in small cell carcinoma of the urinary bladder. Clin Cancer Res 2007; 13:953.</a></li><li><a class="nounderline abstract_t">Neşe N, Kumbaraci BS, Baydar DE, et al. Small Cell Carcinomas of the Bladder Highly Express Somatostatin Receptor Type 2A: Impact on Prognosis and Treatment--A Multicenter Study of Urooncology Society, Turkey. Appl Immunohistochem Mol Morphol 2016; 24:253.</a></li><li><a class="nounderline abstract_t">Pasquier D, Barney B, Sundar S, et al. Small Cell Carcinoma of the Urinary Bladder: A Retrospective, Multicenter Rare Cancer Network Study of 107 Patients. Int J Radiat Oncol Biol Phys 2015; 92:904.</a></li><li><a class="nounderline abstract_t">Trias I, Algaba F, Condom E, et al. Small cell carcinoma of the urinary bladder. Presentation of 23 cases and review of 134 published cases. Eur Urol 2001; 39:85.</a></li><li><a class="nounderline abstract_t">Patel SG, Stimson CJ, Zaid HB, et al. Locoregional small cell carcinoma of the bladder: clinical characteristics and treatment patterns. J Urol 2014; 191:329.</a></li><li><a class="nounderline abstract_t">Siefker-Radtke AO, Dinney CP, Abrahams NA, et al. Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience. J Urol 2004; 172:481.</a></li><li><a class="nounderline abstract_t">Quek ML, Nichols PW, Yamzon J, et al. Radical cystectomy for primary neuroendocrine tumors of the bladder: the university of southern california experience. J Urol 2005; 174:93.</a></li><li><a class="nounderline abstract_t">Swanson PE, Brooks R, Pearse H, Stenzel P. Small cell carcinoma of urinary bladder. Urology 1988; 32:558.</a></li><li><a class="nounderline abstract_t">Siefker-Radtke AO, Kamat AM, Grossman HB, et al. Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer. J Clin Oncol 2009; 27:2592.</a></li><li><a class="nounderline abstract_t">Bex A, de Vries R, Pos F, et al. Long-term survival after sequential chemoradiation for limited disease small cell carcinoma of the bladder. World J Urol 2009; 27:101.</a></li><li><a class="nounderline abstract_t">Lester JF, Hudson E, Barber JB. Bladder preservation in small cell carcinoma of the urinary bladder: an institutional experience and review of the literature. Clin Oncol (R Coll Radiol) 2006; 18:608.</a></li><li><a class="nounderline abstract_t">Lynch SP, Shen Y, Kamat A, et al. Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center. Eur Urol 2013; 64:307.</a></li><li><a class="nounderline abstract_t">Jung K, Ghatalia P, Litwin S, et al. Small-Cell Carcinoma of the Bladder: 20-Year Single-Institution Retrospective Review. Clin Genitourin Cancer 2017; 15:e337.</a></li><li><a class="nounderline abstract_t">Moretto P, Wood L, Emmenegger U, et al. Management of small cell carcinoma of the bladder: Consensus guidelines from the Canadian Association of Genitourinary Medical Oncologists (CAGMO). Can Urol Assoc J 2013; 7:E44.</a></li><li><a class="nounderline abstract_t">Kaushik D, Frank I, Boorjian SA, et al. Long-term results of radical cystectomy and role of adjuvant chemotherapy for small cell carcinoma of the bladder. Int J Urol 2015; 22:549.</a></li><li><a class="nounderline abstract_t">Mukesh M, Cook N, Hollingdale AE, et al. Small cell carcinoma of the urinary bladder: a 15-year retrospective review of treatment and survival in the Anglian Cancer Network. BJU Int 2009; 103:747.</a></li><li><a class="nounderline abstract_t">Asmis TR, Reaume MN, Dahrouge S, Malone S. Genitourinary small cell carcinoma: a retrospective review of treatment and survival patterns at The Ottawa Hospital Regional Cancer Center. BJU Int 2006; 97:711.</a></li><li><a class="nounderline abstract_t">Lohrisch C, Murray N, Pickles T, Sullivan L. Small cell carcinoma of the bladder: long term outcome with integrated chemoradiation. Cancer 1999; 86:2346.</a></li><li><a class="nounderline abstract_t">Walenkamp AM, Sonke GS, Sleijfer DT. Clinical and therapeutic aspects of extrapulmonary small cell carcinoma. Cancer Treat Rev 2009; 35:228.</a></li><li><a class="nounderline abstract_t">Eckert F, Gani C, Bamberg M, Müller AC. Cerebral metastases in extrapulmonary cell carcinoma. Implications for the use of prophylactic cranial irradiation. Strahlenther Onkol 2012; 188:478.</a></li><li><a class="nounderline abstract_t">Ismaili N, Heudel PE, Elkarak F, et al. Outcome of recurrent and metastatic small cell carcinoma of the bladder. BMC Urol 2009; 9:4.</a></li><li><a class="nounderline abstract_t">Bex A, Sonke GS, Pos FJ, et al. Symptomatic brain metastases from small-cell carcinoma of the urinary bladder: The Netherlands Cancer Institute experience and literature review. Ann Oncol 2010; 21:2240.</a></li><li><a class="nounderline abstract_t">Naidoo J, Teo MY, Deady S, et al. Should patients with extrapulmonary small-cell carcinoma receive prophylactic cranial irradiation? J Thorac Oncol 2013; 8:1215.</a></li><li><a class="nounderline abstract_t">Bex A, Nieuwenhuijzen JA, Kerst M, et al. Small cell carcinoma of bladder: a single-center prospective study of 25 cases treated in analogy to small cell lung cancer. Urology 2005; 65:295.</a></li><li><a class="nounderline abstract_t">Wilde L, Ali SM, Solomides CC, et al. Response to Pembrolizumab in a Patient With Chemotherapy Refractory Bladder Cancer With Small Cell Variant Histology: A Case Report and Review of the Literature. Clin Genitourin Cancer 2017; 15:e521.</a></li><li><a class="nounderline abstract_t">Mandelkow T, Blessin NC, Lueerss E, et al. Immune Exclusion Is Frequent in Small-Cell Carcinoma of the Bladder. Dis Markers 2019; 2019:2532518.</a></li></ol></div><div id="topicVersionRevision">Topic 2979 Version 35.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15855652" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Molecular genetic evidence for a common clonal origin of urinary bladder small cell carcinoma and coexisting urothelial carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15329903" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Small cell carcinoma of the urinary bladder: a clinicopathologic analysis of 64 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15656887" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Small cell carcinoma of the bladder: a contemporary clinicopathological study of 51 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15700264" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Small cell carcinoma of the urinary bladder. The Mayo Clinic experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21567387" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : A Surveillance, Epidemiology, and End Results analysis of small cell carcinoma of the bladder: epidemiology, prognostic variables, and treatment trends.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15217423" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Small cell carcinoma of the bladder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28919521" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Treatment Patterns and Survival Outcomes for Patients with Small Cell Carcinoma of the Bladder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17181484" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Small-cell carcinoma of the urinary bladder: diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25042800" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : High frequency of TERT promoter mutation in small cell carcinoma of bladder, but not in small cell carcinoma of other origins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25178641" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Molecular profiling of infiltrating urothelial carcinoma of bladder and nonbladder origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33901032" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Expression of Nectin-4 in Bladder Urothelial Carcinoma, in Morphologic Variants, and Nonurothelial Histotypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10547580" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Chromosomal imbalances in small cell carcinomas of the urinary bladder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17289890" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Epidermal growth factor receptor protein expression and gene amplification in small cell carcinoma of the urinary bladder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25906124" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Small Cell Carcinomas of the Bladder Highly Express Somatostatin Receptor Type 2A: Impact on Prognosis and Treatment--A Multicenter Study of Urooncology Society, Turkey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26104942" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Small Cell Carcinoma of the Urinary Bladder: A Retrospective, Multicenter Rare Cancer Network Study of 107 Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11173944" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Small cell carcinoma of the urinary bladder. Presentation of 23 cases and review of 134 published cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24036236" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Locoregional small cell carcinoma of the bladder: clinical characteristics and treatment patterns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15247709" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15947585" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Radical cystectomy for primary neuroendocrine tumors of the bladder: the university of southern california experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2849228" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Small cell carcinoma of urinary bladder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19414678" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18607595" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Long-term survival after sequential chemoradiation for limited disease small cell carcinoma of the bladder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17051951" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Bladder preservation in small cell carcinoma of the urinary bladder: an institutional experience and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22564397" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27991416" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Small-Cell Carcinoma of the Bladder: 20-Year Single-Institution Retrospective Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23671508" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Management of small cell carcinoma of the bladder: Consensus guidelines from the Canadian Association of Genitourinary Medical Oncologists (CAGMO).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25761779" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Long-term results of radical cystectomy and role of adjuvant chemotherapy for small cell carcinoma of the bladder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19076139" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Small cell carcinoma of the urinary bladder: a 15-year retrospective review of treatment and survival in the Anglian Cancer Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16536759" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Genitourinary small cell carcinoma: a retrospective review of treatment and survival patterns at The Ottawa Hospital Regional Cancer Center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10590377" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Small cell carcinoma of the bladder: long term outcome with integrated chemoradiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19068273" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Clinical and therapeutic aspects of extrapulmonary small cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22418588" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Cerebral metastases in extrapulmonary cell carcinoma. Implications for the use of prophylactic cranial irradiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19500382" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Outcome of recurrent and metastatic small cell carcinoma of the bladder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20427346" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Symptomatic brain metastases from small-cell carcinoma of the urinary bladder: The Netherlands Cancer Institute experience and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23945390" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Should patients with extrapulmonary small-cell carcinoma receive prophylactic cranial irradiation?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15708041" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Small cell carcinoma of bladder: a single-center prospective study of 25 cases treated in analogy to small cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28143711" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Response to Pembrolizumab in a Patient With Chemotherapy Refractory Bladder Cancer With Small Cell Variant Histology: A Case Report and Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31191745" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Immune Exclusion Is Frequent in Small-Cell Carcinoma of the Bladder.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
